Syndax Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Syndax Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Syndax Pharmaceuticals Inc
Rating: 1.198750125
Author: Trendlyne DVM scores

Momentum Trap

about

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a ...

20.63 -0.48 (-2.27%)

140.44% Gain from 52W Low

2.4M

XNAS Volume

XNAS 29 Apr, 2026 5:30 PM (EDT)

Board Meeting

The next board meeting for Syndax Pharma Inc is on 05 May 2026 for the purpose of Syndax Pharmaceuticals Inc First Quarter Earnings Results for 2026 See details

Low Financial Strength

16.7 / 100

Expensive Valuation

7.7 / 100

Technically Neutral

54.9 / 100

Momentum Trap These stocks have weak financials and expensive valuation. Medium technical scores may weaken. Investors should exercise caution View Similar Embed DVM

1Yr Price target upside is 91%

12 analysts

Syndax Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Syndax Pharma Inc Live Stock Price Today, Share Analysis and Chart

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a ...

140.44% Gain from 52W Low

SWOT Analysis

Syndax Pharma Inc Live Price Chart